Your browser doesn't support javascript.
loading
Nicotinic α7 and α4ß2 agonists enhance the formation and retrieval of recognition memory: Potential mechanisms for cognitive performance enhancement in neurological and psychiatric disorders.
McLean, Samantha L; Grayson, Ben; Marsh, Samuel; Zarroug, Samah H O; Harte, Michael K; Neill, Jo C.
Afiliación
  • McLean SL; Bradford School of Pharmacy, University of Bradford, Richmond Road, BD7 1DP, UK.
  • Grayson B; Manchester Pharmacy School, University of Manchester, Oxford Rd, M13 9PT, UK. Electronic address: b.grayson@manchester.ac.uk.
  • Marsh S; Manchester Pharmacy School, University of Manchester, Oxford Rd, M13 9PT, UK.
  • Zarroug SH; Institute for Life Sciences, University of Southampton, University Road, SO17 1BJ, UK.
  • Harte MK; Manchester Pharmacy School, University of Manchester, Oxford Rd, M13 9PT, UK.
  • Neill JC; Manchester Pharmacy School, University of Manchester, Oxford Rd, M13 9PT, UK.
Behav Brain Res ; 302: 73-80, 2016 Apr 01.
Article en En | MEDLINE | ID: mdl-26327238
Cholinergic dysfunction has been shown to be central to the pathophysiology of Alzheimer's disease and has also been postulated to contribute to cognitive dysfunction observed in various psychiatric disorders, including schizophrenia. Deficits are found across a number of cognitive domains and in spite of several attempts to develop new therapies, these remain an unmet clinical need. In the current study we investigated the efficacy of donepezil, risperidone and selective nicotinic α7 and α4ß2 receptor agonists to reverse a delay-induced deficit in recognition memory. Adult female Hooded Lister rats received drug treatments and were tested in the novel object recognition (NOR) task following a 6h inter-trial interval (ITI). In all treatment groups, there was no preference for the left or right identical objects in the acquisition trial. Risperidone failed to enhance recognition memory in this paradigm whereas donepezil was effective such that rats discriminated between the novel and familiar object in the retention trial following a 6h ITI. Although a narrow dose range of PNU-282987 and RJR-2403 was tested, only one dose of each increased recognition memory, the highest dose of PNU-282987 (10mg/kg) and the lowest dose of RJR-2403 (0.1mg/kg), indicative of enhanced cognitive performance. Interestingly, these compounds were also efficacious when administered either before the acquisition or the retention trial of the task, suggesting an important role for nicotinic receptor subtypes in the formation and retrieval of recognition memory.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Recuerdo Mental / Benzamidas / Compuestos Bicíclicos con Puentes / Agonistas Nicotínicos / Reconocimiento en Psicología / Nicotina Límite: Animals Idioma: En Revista: Behav Brain Res Año: 2016 Tipo del documento: Article Pais de publicación: Países Bajos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Recuerdo Mental / Benzamidas / Compuestos Bicíclicos con Puentes / Agonistas Nicotínicos / Reconocimiento en Psicología / Nicotina Límite: Animals Idioma: En Revista: Behav Brain Res Año: 2016 Tipo del documento: Article Pais de publicación: Países Bajos